European Biotechnology--A Question of Control
This article was originally published in Start Up
Executive Summary
European biotech companies have only partnered a third of the development drugs in their collective pipelines. With product-hungry Big Pharma prepared to pay ever-higher prices to in-license, much of the European biotech industry is in a strong position.